JonesResearch downgraded Intellia Therapeutics (NTLA) to Hold from Buy after the company reported along with Q3 results on November 6 that the nex-z treated patient who hit Hy’s Law criteria had passed away. While both lonvo-z for HAE and nex-z for ATTR-CM have durable efficacy, the firm says heightened safety risk and lack and lack of clarity, as well as other market dynamics, prompt it to move to the sidelines.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
- Intellia Reports Favorable Phase 1 Data for Nex-Z
- Intellia announces ‘positive’ follow-up data from ongoing Phase 1 nex-z trial
- Intellia Therapeutics price target lowered to $14 from $25 at Truist
- Cathie Wood Sells Tesla (TSLA) Stock, and Buys This Stock after Q3 Beat